What is the clinical evidence from this study?

Study design: Other. Population: Prostate cancer. Intervention: iCCaRE Consortium Phase 2 activities. Primary outcome: Consortium accomplishments (presentations, publications, grants, community engagement).

What question did this study set out to answer?

The aim is to reduce the burden of prostate cancer among Black men through innovative, community-focused strategies.

April 5, 2026

Abstract 2382: Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium

Key Result

The iCCaRE Consortium Phase 2 advanced global prostate cancer equity in one year, achieving 45 presentations, 17 publications, 16 grant submissions, and reaching over 400 men globally.

Key Points

The aim is to reduce the burden of prostate cancer among Black men through innovative, community-focused strategies.
Launched five full projects and one pilot project across institutions in North America and Africa
Implemented a virtual robot assistant for efficient cancer diagnosis
Initiated cancer care trials and migrant health studies
Expanded genomic and metabolomic research efforts
Developed digital and psychosocial interventions for survivorship
Achieved 45 presentations, 17 publications, and 16 grant submissions within one year
Conducted over 408 live webinars, engaging 400 men worldwide
Developed the PPCD-ViRA for clinical setup
Activated biospecimen collection across several African countries
Trained 13 early-career investigators and 7 prostate cancer advocates

Structured PICO

Population

Black men across the African Diaspora experiencing prostate cancer (CaP) burden

Intervention

iCCaRE Consortium initiatives including global scientific collaboration, community-engaged interventions, digital health technologies (PPCD-ViRA), and workforce development

Outcome

Optimize CaP diagnosis, treatment, and survivorship

The iCCaRE Consortium made substantial progress in one year toward transforming prostate cancer equity globally through multidisciplinary science, digital innovation, and community partnerships.

Abstract

Abstract Background: Black men across the African Diaspora experience a disproportionate burden of prostate cancer (CaP). The Inclusive Cancer Care Research Equity (iCCaRE) Consortium aims to eliminate CaP burden through global scientific collaboration, innovative research, community-engaged interventions, and next-generation workforce development. The primary objective for this Consortium was to optimize CaP diagnosis, treatment, and survivorship through research, research training and education, community engagement and community outreach. The Consortium integrates digital health technologies, community navigation, precision communication and precision science. Methods: Five full projects and one pilot project were launched across partner institutions in North America and Africa. Supported by multiple cores and services, the research activities included (1) implementation of a Point of Prostate Cancer Diagnosis Virtual Robot Assistant (PPCD-ViRA); (3) initiation of a cancer care at home trial; (4) migrant health studies of Caribbean and Sub-Saharan African immigrants; (5) expansion of genomic and metabolomic research; and (6) digital, psychosocial, and survivorship intervention development. Training and dissemination activities were deployed through iCCaRE TV, webinars, and community engagement programs including the Global Prostate Health Dialogue (Glo-PHD). Results: In one year, accomplishments included 45 presentations, 17 publications, 16 grant submissions, and 3 awards. The consortium delivered 408 live webinar engagements and reached more than 400 men globally through Glo-PHD. PPCD-ViRA was fully developed and prepared for clinical deployment (see https://www.youtube.com/watch?v=1mI-HS5R6sk). The African cohort expansion for genomic and metabolomic profiling was activated across several countries, with biospecimen collection underway. Media dissemination generated more than 15,000 views across platforms, including high-impact educational videos (see: www.youtube.com/@iCCaREConsortium). Training achievements included 13 early-career investigators and 7 trained prostate cancer advocates. Conclusions: In just one year, the iCCaRE Consortium Phase 2 made substantial progress toward transforming CaP equity globally. Through multidisciplinary science, digital innovation, and community partnerships, the consortium is building scalable infrastructure to address diagnosis experiences, treatment quality, and survivorship among Black men. Ongoing efforts will continue to advance precision medicine, culturally grounded interventions, and global capacity building. Citation Format: Folakemi T. Odedina, Arnold Merriweather, Roxana S. Dronca, Ernest T. Kaninjing, Solomon Rotimi, Gerardo Colon-Otero, Kimlin Ashing, Ademola A. Popoola, Gladys Asiedu, Opeyemi Bolajoko, Ewan COBRAN, Emelina Asto-Flores, Floyd Willis, Christopher Williams, Monica L. Albertie, Michelle Fudge, Oluwaseyi Toye, Collisa Mahin, Jada Melton, Inclusive Cancer Care Research Equity (iCCaRE) Consortium, Prostate Cancer Transatlantic Consortium (CaPTC). Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2382.

Bookmark